JIA Registry - Abatacept

Clinical Trial Title Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Trial Status Open to Enrollment
Start Date 03/15/2013
Location Legacy Emanuel Medical Center
Trial Type Pediatric Rheumatology
Specific Condition Juvenile Idiopathic Arthritis (JIA)
Description The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) in routine clinical practice, with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Eligibility Criteria

Ages Eligible for Study:  up to 17

Genders Eligible for Study:  Both

Inclusion Criteria:

  • Diagnosis of JIA (any subtype).
  • Age < 18 years at the time of enrollment.
  • Receiving Abatacept at the time of enrollment as per treating physician's decision.
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent.
IRB Number 10608
Notes https://clinicaltrials.gov/ct2/show/NCT01357668
Principal Investigator Daniel Kingsbury, MD
Contact Name Karla Kummer
Contact Phone 503-413-1612
Contact Fax
Contact E-Mail kkummer@lhs.org